- Home
- DEA vs GYRE Comparison
DEA vs GYRE Comparison
Compare DEA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DEA
- GYRE
- Stock Information
- Founded
- DEA 2011
- GYRE 2002
- Country
- DEA United States
- GYRE United States
- Employees
- DEA N/A
- GYRE N/A
- Industry
- DEA Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DEA Real Estate
- GYRE Health Care
- Exchange
- DEA Nasdaq
- GYRE Nasdaq
- Market Cap
- DEA 1.0B
- GYRE 897.1M
- IPO Year
- DEA 2015
- GYRE N/A
- Fundamental
- Price
- DEA $21.91
- GYRE $7.28
- Analyst Decision
- DEA Hold
- GYRE Strong Buy
- Analyst Count
- DEA 5
- GYRE 1
- Target Price
- DEA $27.15
- GYRE $18.00
- AVG Volume (30 Days)
- DEA 468.0K
- GYRE 92.0K
- Earning Date
- DEA 11-04-2025
- GYRE 11-12-2025
- Dividend Yield
- DEA 8.21%
- GYRE N/A
- EPS Growth
- DEA N/A
- GYRE N/A
- EPS
- DEA 0.38
- GYRE 0.02
- Revenue
- DEA $322,861,000.00
- GYRE $102,189,000.00
- Revenue This Year
- DEA $8.62
- GYRE $16.80
- Revenue Next Year
- DEA $6.59
- GYRE $50.29
- P/E Ratio
- DEA $58.00
- GYRE $428.23
- Revenue Growth
- DEA 7.93
- GYRE N/A
- 52 Week Low
- DEA $19.33
- GYRE $6.11
- 52 Week High
- DEA $36.31
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- DEA 37.01
- GYRE 44.66
- Support Level
- DEA $22.39
- GYRE $7.20
- Resistance Level
- DEA $22.89
- GYRE $7.72
- Average True Range (ATR)
- DEA 0.43
- GYRE 0.28
- MACD
- DEA -0.12
- GYRE -0.01
- Stochastic Oscillator
- DEA 5.31
- GYRE 28.58
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.